Clinical trial · Observational
A Study of a New PET Scanner in People With Cancer
Quality Improvement Study of a New Generation of Whole Body PET Scanners
NCT07690917CI-TRIAL-00117226recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Non Small Cell Lung Carcinoma NSCLC | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biograph Vision Quadra scanner | Diagnostic Test | — | UNRESOLVED |
| PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with lung, head and neck, and prostate cancer
- description
- The only investigational aspect of this quality improvement protocol is the acquisition of additional PET/CT imaging data (e.g. breath-hold, dynamic, and/or delayed acquisition) in patients who are already scheduled to receive a PET/CT scan as part of standard of care or under an existing clinical trial.
- interventionNames
- Diagnostic Test: Biograph Vision Quadra scanner
- Diagnostic Test: PET/CT
Primary outcomes (1)
- measure
- image quality
- timeFrame
- 3 years
- description
- Detection of any new/additional lesions on the delayed scan will be recorded using standard clinical interpretation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Eligibility Criteria for objective #1: * Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules. * Patients who are undergoing a planned PET-CT scan at main campus of MSK. * Patients must be ≥ 18 years old Eligibility Criteria for objective #2: * Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously. * Patients with metastatic prostate or head and neck cancer. * Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK. * Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK * Patients must be ≥ 18 years old Eligibility Criteria for objective #3: * Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer). * Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK. * Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection) * Patients must be ≥ 18 years old Exclusion Criteria: * Patients who suffer from claustrophobia. * Women who are pregnant or breast-feeding. * Patients \< 18 years of age
References
Publications (0)
Data not yet available
No reference posted for this study.